Zoetis Option Alert: Dec 19 $140 Calls at the Bid: 435 vs 456 OI; Earnings 11/4 Before Open 

Zoetis Option Alert: Dec 19 $140 Calls at the Bid: 435 @ $12.6 vs 456 OI; Earnings 11/4 Before Open Ref=$147.165

Zoetis Option Alert: Oct 17 $145 Puts at the Bid: 4428 vs 4654 OI; Earnings 11/4 Before Open 

Zoetis Option Alert: Oct 17 $145 Puts at the Bid: 4428 @ $4.0 vs 4654 OI; Earnings 11/4 Before Open Ref=$143.13

Zoetis

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Jim Cramer

News

Media

Le ultime dichiarazioni del noto analista accendono il dibattito tra investitori, mentre il mercato reagisce alle nuove prospettive.

Jim Cramer boccia ZIM: ecco cosa fa discutere gli investitori

Long Ideas

Markets

Trading Ideas

PRCT

Jim Cramer elogia Target per il suo rendimento del 3% e risultati finanziari eccellenti: ecco perché è un&#39;opportunità imperdibile!

Jim Cramer elogia questo titolo: &#34;Il rendimento del 3% è fantastico!&#34;

Zoetis Inc

Ztest Electronics Inc

Press Releases

Zoetis Declares Third Quarter 2025 Dividend

Dr. Mark Stetter Elected to Zoetis Board of Directors

Zoetis Releases 2024 Sustainability Progress Update

Zoetis to Host Webcast and Conference Call on Second Quarter 2025 Financial Results

Zoetis Announces Second Quarter 2025 Results, Raises Full Year 2025 Outlook

Zoetis Announces Pricing of $1.85 Billion of Senior Notes

Zoetis to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Zoetis Receives Positive Opinion from CVMP for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats

Zoetis to Host Webcast and Conference Call on Third Quarter 2025 Financial Results

Zoetis Receives Conditional Approval for Dectomax®-CA1 Injectable for the Prevention and Treatment of New World Screwworm Myiasis in Cattle

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Ligand Pharmaceuticals Incorporated - Common Stock

Ligand Pharmaceuticals

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Date	Put/Call	Strike Price	Exp Date	DTE	Trade Vol	Day Vol	Vol / OI	OI	Trade Type	Sentiment
02:59 PMOct 01, 2025	CALL	$140.00	Dec 19, 2025	74	435	435	95	456	TRADE	NEUTRAL
03:36 PMSep 29, 2025	PUT	$145.00	Oct 17, 2025	11	4437	4428	95	4654	TRADE	NEUTRAL

Comments

Zoetis

Unusual Options Activity for

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO